We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-2.95%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
AUM
$1.13B
AUM Growth
-$333M
Cap. Flow
-$249M
Cap. Flow %
-22.11%
Top 10 Hldgs %
64.02%
Holding
82
New
15
Increased
14
Reduced
31
Closed
17

Top Buys

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$16.3M
2
BRKR icon
Bruker
BRKR
+$13.9M
3
TFX icon
Teleflex
TFX
+$12.7M
4
PCVX icon
Vaxcyte
PCVX
+$12.7M
5
EW icon
Edwards Lifesciences
EW
+$11.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86.03%
2 Miscellaneous 13.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MRVI icon
76
Maravai LifeSciences
MRVI
$1.14B
-336,966
Closed -$2.8M
STAA icon
77
STAAR Surgical
STAA
$1.11B
-91,199
Closed -$3.39M
STOK icon
78
Stoke Therapeutics
STOK
$2.04B
-52,006
Closed -$639K
TRML
79
DELISTED
Tourmaline Bio
TRML
-84,380
Closed -$2.17M
FNA
80
DELISTED
Paragon 28, Inc.
FNA
-749,213
Closed -$5M
NVRO
81
DELISTED
NEVRO CORP.
NVRO
-313,780
Closed -$1.75M
ITCI
82
DELISTED
Intra-Cellular Therapies Inc.
ITCI
-124,491
Closed -$9.11M

Similar funds

Eversept Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Eversept Partners held 82 positions worth $1.13B, down 23% from $1.46B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Eversept Partners withdrew a net $249M in Q4 2024, closing 17 positions and reducing 31 holdings. Its most notable exit was Insmed, an estimated $79.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 89% a quarter earlier, followed by Miscellaneous.

Against the trend, Eversept Partners opened a new position in Bruker worth $13.8M.

  • Eversept Partners's largest Q4 2024 buy was Bruker: 234,934 shares worth $13.8M.
  • Eversept Partners added most to HCA Healthcare in Q4 2024, an estimated $16.3M increase.
  • Eversept Partners's biggest Q4 2024 reduction was Syndax Pharmaceuticals, cutting an estimated $64.4M.
  • Eversept Partners fully exited Insmed in Q4 2024, selling an estimated $79.5M.
  • Eversept Partners's ten largest holdings make up 64% of its $1.13B portfolio in Q4 2024.
  • Eversept Partners opened 15 new positions and closed 17 in Q4 2024.
  • Eversept Partners's portfolio value fell 23% quarter-over-quarter to $1.13B.

Based on Eversept Partners's 13F filing for Q4 2024, filed 14 Feb 2025.